Valeo Financial Advisors LLC Sells 5,979 Shares of Pfizer Inc. (NYSE:PFE)

Valeo Financial Advisors LLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 3.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 173,554 shares of the biopharmaceutical company’s stock after selling 5,979 shares during the period. Valeo Financial Advisors LLC’s holdings in Pfizer were worth $4,816,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. VisionPoint Advisory Group LLC grew its holdings in shares of Pfizer by 52,350.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the period. GoalVest Advisory LLC grew its holdings in shares of Pfizer by 304.9% during the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after buying an additional 811 shares during the last quarter. Creekmur Asset Management LLC purchased a new stake in Pfizer in the 4th quarter valued at approximately $32,000. Trivant Custom Portfolio Group LLC boosted its stake in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners purchased a new position in Pfizer during the fourth quarter worth $36,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.13 during midday trading on Wednesday, reaching $27.70. 12,367,366 shares of the company traded hands, compared to its average volume of 40,419,469. The firm has a market capitalization of $156.96 billion, a price-to-earnings ratio of -462.33, a price-to-earnings-growth ratio of 1.10 and a beta of 0.69. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $37.80. The firm’s fifty day moving average price is $27.96 and its two-hundred day moving average price is $27.71. The company has a quick ratio of 0.78, a current ratio of 1.05 and a debt-to-equity ratio of 0.66.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period in the previous year, the company posted $1.23 earnings per share. The firm’s revenue was down 19.5% on a year-over-year basis. On average, equities analysts expect that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Investors of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 6.06%. The ex-dividend date is Thursday, July 25th. Pfizer’s payout ratio is currently -2,800.00%.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Morgan Stanley lifted their price objective on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. BMO Capital Markets restated an “outperform” rating and set a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research note on Wednesday, June 26th. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $35.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.